Search

Your search keyword '"Moes-Sosnowska, Joanna"' showing total 38 results

Search Constraints

Start Over You searched for: Author "Moes-Sosnowska, Joanna" Remove constraint Author: "Moes-Sosnowska, Joanna"
38 results on '"Moes-Sosnowska, Joanna"'

Search Results

2. The Advantage of Targeted Next-Generation Sequencing over qPCR in Testing for Druggable EGFR Variants in Non-Small-Cell Lung Cancer.

3. Genome-wide significant risk associations for mucinous ovarian carcinoma (vol 47, pg 888, 2015)

5. Epigenetic analysis leads to identification of HNF1B as a subtype-specific susceptibility gene for ovarian cancer

6. Clinical significance of TP53 alterations in advanced NSCLC patients treated with EGFR, ALK and ROS1 tyrosine kinase inhibitors: An update.

7. Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer

8. FGFR1–4 RNA-Based Gene Alteration and Expression Analysis in Squamous Non-Small Cell Lung Cancer

9. PROM1, CXCL8, RUNX1, NAV1 and TP73 genes as independent markers predictive of prognosis or response to treatment in two cohorts of high-grade serous ovarian cancer patients

10. BRCA2 Polymorphic Stop Codon K3326X and the Risk of Breast, Prostate, and Ovarian Cancers

12. Common variants at the CHEK2 gene locus and risk of epithelial ovarian cancer

13. FGFR1 gene aberrations and FGFR1 protein expression in squamous non-small cell lung cancer (Sq-NSCLC)

14. Molecular profiling of Sq-NSCLC with enhanced FGFR1-4 and MET gene expression – NGS pilot study

15. The EGFR mutation detection in NSCLC by Next Generation Sequencing (NGS): cons and pros

18. Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer

19. Clinical importance of the EMSY gene expression and polymorphisms in ovarian cancer

20. Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer

21. Assessment of variation in immunosuppressive pathway genes reveals TGFBR2 to be associated with risk of clear cell ovarian cancer

22. PALB2, CHEK2 and ATM rare variants and cancer risk: data from COGS

23. Genome-wide significant risk associations for mucinous ovarian carcinoma (vol 47, pg 888, 2015)

24. Assessment of variation in immunosuppressive pathway genes reveals TGFBR2 to be associated with risk of clear cell ovarian cancer

25. Clinical importance of FANCD2, BRIP1, BRCA1, BRCA2and FANCFexpression in ovarian carcinomas

28. Ovarian small cell carcinoma of hypercalcemic type – evidence of germline origin and smarca4 gene inactivation. a pilot study

29. Common variants at theCHEK2gene locus and risk of epithelial ovarian cancer

30. Genome-wide significant risk associations for mucinous ovarian carcinoma

31. PALB2, CHEK2 and ATM rare variants and cancer risk: data from COGS

32. Genome-wide significant risk associations for mucinous ovarian carcinoma (vol 47, pg 888, 2015)

33. Assessment of variation in immunosuppressive pathway genes reveals TGFBR2 to be associated with risk of clear cell ovarian cancer

34. PALB2, CHEK2 and ATM rare variants and cancer risk : data from COGS

35. Clinical significance of TP53 alterations in advanced NSCLC patients treated with EGFR, ALK and ROS1 tyrosine kinase inhibitors: An update.

36. PALB2, CHEK2 and ATM rare variants and cancer risk: data from COGS.

37. Assessment of variation in immunosuppressive pathway genes reveals TGFBR2 to be associated with risk of clear cell ovarian cancer.

38. BRCA2 Polymorphic Stop Codon K3326X and the Risk of Breast, Prostate, and Ovarian Cancers.

Catalog

Books, media, physical & digital resources